Literature DB >> 6701939

Chronic antihypertensive treatment in the rat reverses hypertension-induced changes in cerebral blood flow autoregulation.

S Vorstrup, D I Barry, J O Jarden, U G Svendsen, O Braendstrup, D I Graham, S Strandgaard.   

Abstract

Cerebral blood flow (CBF) autoregulation was studied in renal hypertensive rats receiving chronic antihypertensive treatment. Young Wistar Kyoto rats (WKY) were made hypertensive by the Loomis procedure i.e. partial infarction of one kidney with contralateral nephrectomy. Systolic tail blood pressure was measured at 2-week intervals throughout the study. After two months, by which time the rats had been severely hypertensive for 5-6 weeks, antihypertensive treatment was begun; reserpine, dihydralazine and hydrochlorothiazide were administered in the drinking water. Blood pressure fell rapidly to normotensive levels and remained so. Following two months of antihypertensive treatment, the lower blood pressure limit of CBF autoregulation was studied during controlled bleeding. In age-matched untreated renal hypertensive WKY, the lower limit of autoregulation was in the mean arterial pressure range 90-109 mm Hg, as compared to 50-69 mm Hg in age-matched normotensive WKY. In contradistinction to the untreated rats, the treated rats had a normal lower limit of autoregulation, i.e. 50-69 mm Hg. It was inferred that the reversal of the functional change in CBF autoregulation reflected reversal of hypertension-induced cerebrovascular hypertrophy/hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6701939     DOI: 10.1161/01.str.15.2.312

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  9 in total

1.  What is the optimal anesthetic protocol for measurements of cerebral autoregulation in spontaneously breathing mice?

Authors:  Zhenghui Wang; Beat Schuler; Olga Vogel; Margarete Arras; Johannes Vogel
Journal:  Exp Brain Res       Date:  2010-10-24       Impact factor: 1.972

Review 2.  Cerebral blood flow in the elderly: impact of hypertension and antihypertensive treatment.

Authors:  S Strandgaard
Journal:  Cardiovasc Drugs Ther       Date:  1991-01       Impact factor: 3.727

3.  On the effect of calcium antagonists on cerebral blood flow in rats. A comparison of nimodipine and flunarizine.

Authors:  M Zumkeller; H E Heissler; H Dietz
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

4.  Bradykinin antagonist counteracts the acute effect of both angiotensin-converting enzyme inhibition and of angiotensin receptor blockade on the lower limit of autoregulation of cerebral blood flow.

Authors:  Sigurdur T Sigurdsson; Olaf B Paulson; Arne Høj Nielsen; Svend Strandgaard
Journal:  J Cereb Blood Flow Metab       Date:  2013-12-11       Impact factor: 6.200

Review 5.  The effects of hypertension on the cerebral circulation.

Authors:  Paulo W Pires; Carla M Dams Ramos; Nusrat Matin; Anne M Dorrance
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-12       Impact factor: 4.733

Review 6.  Angiotensin converting enzyme inhibition and cerebral circulation--a review.

Authors:  G Waldemar; O B Paulson
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

7.  Calcitonin gene-related peptide (CGRP) receptors are important to maintain cerebrovascular reactivity in chronic hypertension.

Authors:  Zhenghui Wang; Belén Cantó Martorell; Thomas Wälchli; Olga Vogel; Jan Fischer; Walter Born; Johannes Vogel
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

8.  Impaired dynamic cerebral autoregulation is associated with the severity of neuroimaging features of cerebral small vessel disease.

Authors:  Zhaojun Liu; Hongyin Ma; Zhen-Ni Guo; Le Wang; Yang Qu; Lei Fan; Xingliang Liu; Jie Liu; Yuanyuan Zhu; Yi Yang
Journal:  CNS Neurosci Ther       Date:  2021-12-11       Impact factor: 5.243

Review 9.  Hypertension, dietary salt and cognitive impairment.

Authors:  Monica M Santisteban; Costantino Iadecola
Journal:  J Cereb Blood Flow Metab       Date:  2018-10-08       Impact factor: 6.960

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.